The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Progression Free Survival, Overall Survival, and Relapse Rate in Endometrioid Ovarian Cancer and Synchronous Endometrial-Ovarian Endometrioid Cancer (SEO-EC): Results from a Large Retrospective Analysis
Open accessAbstract
Background and Objectives: We aimed to evaluate Progression Free Survival (PFS), Overall Survival (OS), and relapse rate in women affected by endometrioid ovarian cancer and synchronous endometrial-ovarian endometrioid cancer (SEO-EC). As secondary outcome, we assessed whether systematic pelvic and para-aortic lymphadenectomy could be considered a determinant of relapse rate in this population. Materials and Methods: We performed a retrospective analysis of women with diagnosis of endometrioid ovarian cancer or SEO-EC between January 2010 to September 2020, and calculated PFS, OS and relapse rate. Results: In almost all the patients (97.6%) who underwent systematic pelvic and para-aortic lymphadenectomy, there were no lymph node metastases confirmed by histology. We did not find a significant difference (p = 0.6570) for the rate of relapse in the group of women who underwent systematic pelvic and para-aortic lymphadenectomy (4/42; 9.5%) compared with the group of women who did not undergo the same procedure (1/21; 4.8%). During a median follow-up was 23 months, both PFS and OS were excellent. Conclusions: Women affected by early-stage low-grade endometrioid cancer and SEO-EC without apparent lymph node involvement at pre-operative imaging showed a very low rate of lymph node metastasis and similar relapse rate with or without lymphadenectomy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
For women with synchronous endometrial-ovarian endometrioid cancer affected by early-stage low-grade endometrioid cancer without apparent lymph node involvement at preoperative imaging, the rate of lymph node metastasis is very low and relapse rate is similar with or without lymphadenectomy.
“Pecorino et al., 2022, shows that for women with synchronous endometrial–ovarian endometrioid cancer affected by early-stage low-grade endometrioid cancer without apparent lymph node involvement at preoperative imaging have a very low rate of lymph node metastasis and similar relapse rate with or without lymphadenectomy [23].”
From Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review (2024) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benchimol, E. I., Smeeth, L., Guttmann, A., Harron, K., Moher, D., Petersen, I., Sørensen, H. T., von Elm, E., Langan, S. M., & RECORD Working Committee (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001885 · Cited by 5,749
Epidemiology of ovarian cancer: a review
Reid Brett, M., Reid Brett, M., Permuth, J. B., Sellers Thomas, A., Permuth, J. B., & Sellers Thomas, A. (2017) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0084 · Cited by 1,593
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R. E., Fox, S. B., Lade, S., Johnson, D., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,458
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
Prat, J. (2013) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2013.10.001 · Cited by 1,366
Epidemiology of epithelial ovarian cancer
Webb, P. M., & Jordan, S. J. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.08.006 · Cited by 998
Fagotti, A., Ferrandina, M. G., Vizzielli, G., Pasciuto, T., Fanfani, F., Gallotta, V., Margariti, P. A., Chiàntera, V., Costantini, B., Alletti, S. G., et al. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001640 · Cited by 455
Colombo, N., Sessa, C., du Bois, A., Ledermann, J. A., McCluggage, W. G., McNeish, I. A., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I. B., et al. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000308 · Cited by 428
Prat, J., D′Angelo, E., & Espinosa, Í. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.06.018 · Cited by 283
Histologic Transformation of Benign Endometriosis to Early Epithelial Ovarian Cancer
de la Cuesta, R. S., Eichhorn, J. H., Rice, L. W., Fuller, A. F., Nikrui, N., & Goff, B. A. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0032 · Cited by 272
Schultheis, A. M., Ng, C. K. Y., Filippo, M. R. D., Piscuoglio, S., Macedo, G. S., Gatius, S., Perez‐Mies, B., Soslow, R. A., Lim, R. S., Viale, A. J., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv427 · Cited by 257
Low‐grade serous carcinomas of the ovary contain very few point mutations
Jones, S., Wang, T., Kurman, R. J., Nakayama, K., Velculescu, V. E., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., & Shih, I. (2011) · The Journal of Pathology · doi:10.1002/path.3967 · Cited by 221
FIGO staging of gynecologic cancer
Pecorelli, S., Benedet, J. L., Creasman, W. T., & Shepherd, J. H. (1999) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(98)00234-3 · Cited by 183
Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome
Hollis, R. L., Thomson, J. P., Stanley, B., Churchman, M., Meynert, A. M., Rye, T., Bartos, C., Iida, Y., Croy, I., Mackean, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18819-5 · Cited by 141
The Evolution of Ovarian Carcinoma Subclassification
Köbel, M., & Kang, E. Y. (2022) · Cancers · doi:10.3390/cancers14020416 · Cited by 139
Uccella, S., Nero, C., Vizza, E., Vargiu, V., Corrado, G., Bizzarri, N., Ghezzi, F., Cosentino, F., Turco, L. C., Fagotti, A., et al. (2019) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.05.005 · Cited by 83
Stewart, C. J. R., Crum, C. P., McCluggage, W. G., Park, K. J., Rutgers, J. K. L., Oliva, E., Malpica, A. L., Parkash, V., Matías‐Guiu, X., & Ronnett, B. M. (2018) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000553 · Cited by 77
Obesity and female malignancies
Benedetto, C., Salvagno, F., Canuto, E. M., & Gennarelli, G. (2015) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2015.01.003 · Cited by 49
Nasioudis, D., Chapman‐Davis, E., Witkin, S. S., & Holcomb, K. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.11.038 · Cited by 49
A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer
Chen, S., Li, Y., Qian, L., Deng, S., Liu, L., Xiao, W., & Zhou, Y. Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668151 · Cited by 47
Casarin, J., Bogani, G., Piovano, E., Falcone, F., Ferrari, F. G., Odicino, F. E., Puppo, A., Bonfiglio, F., Donadello, N., Pinelli, C., et al. (2020) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2020.31.e64 · Cited by 32
Self-citationEngqvist, H., Parris, T., Biermann, J., Rönnerman, E., Larsson, P., Sundfeldt, K., Kovács, A., Karlsson, P., & Helou, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-64794-8 · Cited by 27
Chen, J., Yin, J., Li, Y., Gu, Y. L., Wang, W. T., Shan, Y., Wang, Y., Qin, M., Cai, Y., Jin, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.705720 · Cited by 25
Uccella, S., Garzon, S., Bosco, M., Porcari, I., Lanzo, G., Laganà, A. S., Chiàntera, V., Cliby, W. A., Mariani, A., Franchi, M. P., et al. (2022) · Gynecologic and Obstetric Investigation · doi:10.1159/000525126 · Cited by 24
Self-citationEndometriosis and Endometriosis-Associated Ovarian Cancer (EAOC)
Pejovic, T. B., Thisted, S., White, M., & Nezhat, F. R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-38474-6_5 · Cited by 20
Donna, M. C. D., Giallombardo, V., Balbo, G. L., Cucinella, G., Sozzi, G., Capozzi, V. A., Abbate, A., Laganà, A. S., Garzon, S., & Chiàntera, V. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123332 · Cited by 17
Self-citationIdeal Lymph Node Number for Ovarian Malignancies
Karadağ, İ., & Karakaya, S. (2022) · Cureus · doi:10.7759/cureus.20869 · Cited by 2
Flagged first, then by citations
Cited by
Sorted by citations
Gullo, G., Cucinella, G., Chiàntera, V., Dellino, M., Cascardi, E., Török, P., Herman, T., Garzon, S., Uccella, S., & Laganà, A. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010811 · Cited by 52
Self-citationMalignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review
Alaert, J., Lancelle, M., Timmermans, M., Tanos, P., Nisolle, M., & Karampelas, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13082282 · Cited by 9
“…that for women with synchronous endometrial–ovarian endometrioid cancer affected by early-stage low-grade endometrioid cancer without apparent lymph node involvement at preoperative imaging have a very low rate of lymph node metastasis and similar relapse rate with or without lymphadenectomy [23].”
BackgroundLaparoscopic prediction of primary cytoreducibility of epithelial ovarian cancer
D’Augè, T. G., Giannini, A., Cuccu, I., Angelis, E. D., Donato, V. D., Muzii, L., D’Oria, O., Chiantera, V., Gerli, S., Caserta, D., et al. (2024) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.24.05452-6 · Cited by 7
Self-citationKabeya, C., Khaled, C., Karaki, J., Polastro, L., Moreau, M., Bucella, D., Fastrez, M., & Liberale, G. (2024) · Current Oncology · doi:10.3390/curroncol31120579 · Cited by 2
(2023) · European Journal of Gynaecological Oncology · doi:10.22514/ejgo.2023.112 · Cited by 2
A novel prognostic score of recurrence for endometrial cancer patients with staging surgery
Maehana, T., Kawahara, N., Kamibayashi, J., Matsuoka, M., Waki, K., Kawaguchi, R., & Kimura, F. (2024) · BMC Women s Health · doi:10.1186/s12905-024-03528-8 · Cited by 1
Pappa, C., Aggarwal, A., El‐Tawab, S. S., Nistor, S. I., Thorne, J. E., Sadeghi, N., Manek, S., Gaitskell, K. L., Dhar, S., Conforti, J., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13102381 · Cited by 1
Kolasa, E., Paluch, A., Satora, M., & Kułak, K. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.40.01.005
(2023) · European Journal of Gynaecological Oncology · doi:10.22514/ejgo.2023.067
Ramachandran, R., Nistor, S. I., Gietzmann, W., Symons, N. R. A., & majd, H. S. (2024) · Clinical Case Reports · doi:10.1002/ccr3.9148
Nanotechnology in Ovarian Cancer: Innovations in Diagnostics and Treatments
Younus, I., Siddiq, A., Kanwal, N., Aneeq, M., Fatima, N., ibrar, M., & Maqbool, T. (2026) · Current Women s Health Reviews · doi:10.2174/0115734048450487260226054637
Deciphering the Pleiotropic Role of ARID1a and RIF1 in Endometrioid Ovarian Cancer
Kordowitzki, P., Velho, R. V., Bock, S., Sehouli, J., & Mechsner, S. (2026) · Cells · doi:10.3390/cells15111036
Metadata
- Authors
- Pecorino, B., Laganà, A. S., Chiantera, V., Ferrara, M., Di Stefano, A. B., Di Donna, M. C., Sorrentino, F., Nappi, L., Mikuš, M., & Scollo, P.
- Affiliations
- Università degli Studi di Enna Kore (IT)
- University of Palermo (IT)
- Unit of Gynecologic Oncology, ARNAS “Civico-Di Cristina-Benfratelli”, 90127 Palermo, Italy
- Maternal and Child Department, Obstetrics and Gynecology Cannizzaro Hospital, University of Enna “Kore”, 95126 Catania, Italy
- University of Foggia (IT)
- University Hospital Centre Zagreb (HR)
- Corresponding author
- Laganà, Antonio Simone
- ORCID
- Venue
- Medicina
- Publisher
- MDPI AG
- Published
- 2022-11-23
- Volume
- 58
- Issue
- 12
- Pages
- 1706
- ISSN
- 1010-660X (ISSN-L)
- 1648-9144
- PMC
- PMC9784653
- OpenAlex
- W4309722764
- Cited by
- 12
- References
- 26
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 4
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medicina (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- endometrioid ovarian cancer, progression-free survival, overall survival, relapse rate, pelvic lymphadenectomy, para-aortic lymphadenectomy, lymph node metastasis
- MeSH terms
- Carcinoma, Ovarian Epithelial, Progression-Free Survival, Female, Humans, Lymph Node Excision, Neoplasm Staging, Ovarian Neoplasms, Recurrence, Retrospective Studies, Survival Rate, Endometrial Neoplasms, Carcinoma, Endometrioid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
